Vantage Biosciences today announced that it has completed patient enrollment in the Phase 2 SeeClear study (VX01-DR-201) of oruvestat (VX-01), an investigational, orally administered inhibitor of ...

Survival models using EHR data predicted progression from NPDR or DME to PDR in type 2 diabetes patients. Key risk factors for progression included age, race, NPDR severity, and diabetic nephropathy.

LONDON – Long-established, but often forgotten, primary care tools, including the swinging light test and the lipid-lowering drug fenofibrate, may help detect early worsening of diabetic retinopathy ...

For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the annual meeting of the ...

Individuals with type 2 diabetes — with or without retinopathy — had higher risks for incident Alzheimer’s disease and dementia than those without the blood sugar disorder. Among patients with ...

Please provide your email address to receive an email when new articles are posted on . INDIANAPOLIS — APX3330, an investigational oral treatment for diabetic retinopathy, reduced the development of ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — Early pars plana vitrectomy may be a low-cost, definitive treatment for patients with ...

Use of the cholesterol-lowering drug fenofibrate had a modest but statistically significant association with reduced risk of vision-threatening diabetic retinopathy (VTDR), according to results of a ...

The five human senses include sight, hearing, smell, taste, and touch. While each of these matter for different reasons, they aren't perceived as being equal. For instance, according to a YouGov ...

While rapid weight-loss with bariatric surgery or drugs might temporarily worsen diabetic retinopathy as blood sugar levels are rapidly corrected, the low overall risk likely doesn't outweigh the ...